Table 3.
Relationship between tumor- and host-related characteristics and disease-free survival in 255 patients with endometrial cancer
| Variable | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Age (years) (≤ 56 vs. > 56) | 3.59 (1.39, 9.29) | 0.0085 | |||
| Histology (endometrioid vs. others) | 7.81 (3.05, 19.97) | < 0.0001 | |||
| Histologic grade (G1 vs. G2-G3) | 10.81 (2.52, 46.41) | 0.0014 | 9.57 (2.08, 44.01) | 0.0037 | |
| FIGO stage (I-II vs. III-IV) | 15.09 (6.03, 37.78) | < 0.0001 | 8.14 (3.14, 21.11) | < 0.0001 | |
| LVSI (absent vs. present) | 8.29 (3.43, 20.03) | < 0.0001 | |||
| CA-125 (unit/mL) (≤ 48.1 vs. > 48.1) | 5.54 (2.20, 13.97) | < 0.0001 | |||
| Albumin (g/dL) (≤ 4.4 vs. > 4.4) | 0.21 (0.06, 0.73) | 0.0138 | |||
| WBC (per µL) (≤ 5410 vs. > 5410) | 5.86 (0.79, 43.31) | 0.0848 | |||
| ANC (per µL) (≤ 3665.1 vs. > 3665.1) | 3.01 (1.01, 8.94) | 0.0478 | |||
| ALC (per µL) (≤1526.9 vs. >1526.9) | 0.25 (0.10, 0.60) | 0.0019 | |||
| AMC (per µL) (≤ 528.4 vs. > 528.4) | 4.83 (2.01, 11.64) | < 0.0001 | |||
| Hemoglobin (g/dL) (≤11.7 vs. >11.7) | 0.31 (0.13, 0.74) | 0.0079 | |||
| MCV (fL) (≤ 90 vs. > 90) | 3.16 (1.26, 7.91) | 0.0139 | |||
| Platelet (x 103/µL) (≤204 vs. >204) | 0.34 (0.13, 0.89) | 0.0282 | |||
| NLR (≤ 2.44 vs. > 2.44) | 3.68 (1.55, 8.76) | 0.0032 | |||
| PLR (≤ 190.78 vs. > 190.78) | 3.08 (1.30, 7.32) | 0.0108 | |||
| LMR (≤ 3.28 vs. > 3.28) | 0.10 (0.04, 0.25) | < 0.0001 | 0.10 (0.03, 0.32) | < 0.0001 | |
HRs were obtained from Cox's proportional hazard model.
HR, hazard ratio; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion;CA-125, cancer antigen 125; WBC, white blood cell; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; MCV, mean corpuscular volume; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR, lymphocyte-monocyte ratio